New analysis of Uplizna for neuromyelitis optica spectrum disorder is published in Neurology Neuroimmunology & Neuroinflammation – Horizon Therapeutics

Horizon Therapeutics plc announced the publication of a new analysis of the pivotal Phase II/III N-MOmentum trial for Uplizna (inebilizumab-cdon), assessing the potential for reduced risk of worsening disability in those living with neuromyelitis optica spectrum disorder (NMOSD). These data are published in the May issue of Neurology Neuroimmunology & Neuroinflammation. Uplizna is the first and only FDA-approved anti-CD19 B-cell depleting humanized monoclonal antibody for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive NMOSD

A separate analysis of the Phase II/III N-MOmentum trial published in the Annals of Neurology highlights a potential new biomarker of disease activity in NMOSD. Currently there is no blood test that can effectively monitor disease activity, severity of attacks or treatment impact for NMOSD patients. But research has indicated that serum glial fibrillary acidic protein (sGFAP) may be a relevant biomarker for the disease.

See- Marignier R, et al. “Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder”-. Neurol Neuroimmunol Neuroinflamm. 2021;8:e978.https://nn.neurology.org/content/8/3/e978.

See-” Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker”. Ann Neurol. 2021;00:1-16. Available at: https://onlinelibrary.wiley.com/doi/full/10.1002/ana.26067.